Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: A double-blind placebo-controlled trial

Journal of Clinical Oncology

Volumn 31, Issue 10, 2013, Pages 1271-1276

  Del Fabbro, Egidio ^a   Dev, Rony ^a   Hui, David ^a   Palmer, Lynn ^a   Bruera, Eduardo ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN; PLACEBO;

ADULT; ADVANCED CANCER; ANXIETY DISORDER; APPETITE; ARTICLE; BODY COMPOSITION; BODY WEIGHT; CACHEXIA; CANCER PAIN; CONTROLLED STUDY; DEPRESSION; DIGESTIVE SYSTEM CANCER; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG FATALITY; EVENING DOSAGE; FATIGUE; FEMALE; HUMAN; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SLEEP; SYMPTOM; TREATMENT DURATION; WELLBEING;

ADULT; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; APPETITE; BODY WEIGHT; CACHEXIA; DEPRESSION; DOUBLE-BLIND METHOD; FATIGUE; FEMALE; HUMANS; MALE; MELATONIN; MIDDLE AGED; NEOPLASMS; QUALITY OF LIFE; QUESTIONNAIRES; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84876070234     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.43.6766     Document Type: Article

References (29)

1. Reiter RJ, Tan DX, Manchester LC, et al: Medical implications of melatonin: Receptor-mediated and receptor-independent actions. Adv Med Sci 52:11-28, 2007
2. Tan DX, Manchester LC, Terron MP, et al: One molecule, many derivatives: A never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res 42:28-42, 2007 (Pubitemid 44924323)
3. Bubenik GA: Gastrointestinal melatonin: Localization, function, and clinical relevance. Dig Dis Sci 47:2336-2348, 2006
4. Raghavendra V, Kulkarni SK: Melatonin reversal of DOI-induced hypophagia in rats; possible mechanism by suppressing 5-HT(2A) receptor-mediated activation of HPA axis. Brain Res 860:112-118, 2000 (Pubitemid 30155843)
5. Motilva V, Cabeza J, Alarcón de la Lastra C: New issues about melatonin and its effects on the digestive system. Curr Pharm Des 7:909-931, 2001
6. Kadekaro AL, Andrade LN, Floeter-Winter LM, et al: MT-1 melatonin receptor expression increases the antiproliferative effect of melatonin on S-91 murine melanoma cells. J Pineal Res 36:204-211, 2004 (Pubitemid 38429287)
7. Blask DE, Dauchy RT, Sauer LA, et al: Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: Melatonin receptor-mediated inhibition of tumor linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. Carcinogenesis 25:951-960, 2004 (Pubitemid 38886081)
8. Yan JJ, Shen F, Wang K, et al: Patients with advanced primary hepatocellular carcinoma treated by melatonin and transcatheter arterial chemoembolization: A prospective study. Hepatobiliary Pancreat Dis Int 1:183-186, 2002 (Pubitemid 36748198)
9. Lissoni P, Paolorossi F, Tancini G, et al: Is there a role for melatonin in the treatment of neoplastic cachexia? Eur J Cancer 32A:1340-1343, 1996 (Pubitemid 26246707)
10. Lissoni P: Is there a role for melatonin in supportive care? Support Care Cancer 10:110-116, 2002
11. Lissoni P: Biochemotherapy with standard chemotherapies plus the pineal hormone melatonin in the treatment of advanced solid neoplasms. Pathol Biol (Paris) 55:201-204, 2007
12. Chang VT, Hwang SS, Feuerman M: Validation of the Edmonton Symptom Assessment Scale. Cancer 88:2164-2171, 2000 (Pubitemid 30233220)
13. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993 (Pubitemid 23071057)
14. Ribaudo JM, Cella D, Hahn EA, et al: Revalidation and shortening of the Functional Assessment of Anorexia/Cachexia Therapy (FAACT) questionnaire. Qual Life Res 9:1137-1146, 2000 (Pubitemid 32452957)
15. Bruera E, Macmillan K, Kuehn N, et al: A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status, and other symptoms in patients with advanced cancer. Cancer 66:1279-1282, 1990 (Pubitemid 20310671)
16. Bruera E, Ernst S, Hagen N, et al: Effectiveness of megestrol acetate in patients with advanced cancer: A randomized, double-blind, crossover study. Cancer Prev Control 2:74-78, 1998 (Pubitemid 28222429)
17. Herxheimer A, Petrie KJ: Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev 2:CD001520, 2002
18. Reference deleted
19. Lissoni P: The pineal gland as a central regulator of cytokine network. Neuro Endocrinol Lett 20:343-349, 1999
20. Lissoni P: Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms. Ann N Y Acad Sci 917:560-567, 2000
21. Persson C, Glimelius B, Ronnelid J, et al: Impact of fish oil and melatonin on cachexia in patients with advanced gastrointestinal cancer: A randomized pilot study. Nutrition 21:170-178, 2005 (Pubitemid 40255726)
22. Fearon K, Strasser F, Anker SD, et al: Definition and classification of cancer cachexia: An international consensus. Lancet Oncol 12:489-495, 2011
23. Lundholm K, Gunnebo L, Körner U, et al: Effects by daily long term provision of ghrelin to unselected weight-losing cancer patients: A randomized double-blind study. Cancer 116:2044-2052, 2010
24. Murphy RA, Mourtzakis M, Chu QS, et al: Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy. Cancer 117:1775-1782, 2011
25. Bruera E, El Osta B, Valero V, et al: Donepezil for cancer fatigue: A double-blind, randomized, placebo-controlled trial. J Clin Oncol 25:3475-3481, 2007 (Pubitemid 47310886)
26. Bruera E, Strasser F, Palmer JL, et al: Effect of fish oil on appetite and other symptoms in patients with advanced cancer and anorexia/cachexia: A double-blind, placebo-controlled study. J Clin Oncol 21:129-134, 2003
27. Di Sebastiano KM, Mourtzakis M: A critical evaluation of body composition modalities used to assess adipose and skeletal muscle tissue in cancer. Appl Physiol Nutr Metab 37:811-821, 2012
28. Trutschnigg B, Kilgour RD, Reinglas J, et al: Precision and reliability of strength (Jamar vs. Biodex handgrip) and body composition (dual-energy X-ray absorptiometry vs. bioimpedance analysis) measurements in advanced cancer patients. Appl Physiol Nutr Metab 33:1232-1239, 2008
29. Thomson R, Brinkworth GD, Buckley JD, et al: Good agreement between bioelectrical impedance and dual-energy X-ray absorptiometry for estimating changes in body composition during weight loss in overweight young women. Clin Nutr 26:771-777, 2007 (Pubitemid 350082496)